• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Gallagher Neil

    5/2/25 4:04:44 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FHTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Gallagher Neil

    (Last) (First) (Middle)
    500 TECHNOLOGY SQUARE
    SUITE 700

    (Street)
    CAMBRIDGE MA 02139

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Foghorn Therapeutics Inc. [ FHTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (Right to buy) $4.16 05/01/2025 A 50,000 (1) 04/30/2035 Common Stock 50,000 $4.16 50,000 D
    Explanation of Responses:
    1. The options will vest as to one-third of the underlying shares of common stock on each of the first three anniversaries of the date of grant, subject to the recipient's continuing service on the board of directors.
    Remarks:
    /s/ Michael LaCascia, Attorney-in-Fact for Neil Gallagher 05/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FHTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FHTX

    DatePrice TargetRatingAnalyst
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    1/30/2025$10.00Buy
    B. Riley Securities
    9/3/2024$18.00Buy
    Jefferies
    8/19/2024$20.00Outperform
    Evercore ISI
    3/28/2023$10.00Buy
    BofA Securities
    1/5/2023$20.00Outperform
    BMO Capital Markets
    12/15/2021$23.00 → $26.00Overweight
    Morgan Stanley
    11/22/2021$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $FHTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens JMP initiated coverage on Foghorn Therapeutics with a new price target

    Citizens JMP initiated coverage of Foghorn Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

    4/23/25 8:16:18 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Foghorn Therapeutics with a new price target

    B. Riley Securities initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $10.00

    1/30/25 7:55:02 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Foghorn Therapeutics with a new price target

    Jefferies initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $18.00

    9/3/24 7:47:52 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    SEC Filings

    View All

    SEC Form 10-Q filed by Foghorn Therapeutics Inc.

    10-Q - Foghorn Therapeutics Inc. (0001822462) (Filer)

    8/5/25 7:31:44 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foghorn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

    8/5/25 7:30:12 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foghorn Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

    7/1/25 4:40:46 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Smith Ian F

    4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    6/17/25 4:29:40 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parshall B Lynne

    4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    6/17/25 4:29:16 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mendelsohn Michael

    4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    6/17/25 4:28:43 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

    FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical synergistic benefit of FHD-909 in combination with pembrolizumab and KRAS inhibitors reinforces significant potential in NSCLC Selective CBP degrader on track for IND-enabling studies, targeting an IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader, with program updates expected in Q4 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $198.7 million as of June 30, 2025; cash runway into 2028 CAMBRIDG

    8/5/25 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

    Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod

    7/1/25 6:30:00 AM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $FHTX
    Leadership Updates

    Live Leadership Updates

    View All

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Ted Myles Joins Cellarity as Chief Executive Officer

    Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

    5/12/25 8:00:00 AM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

    CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher

    5/1/25 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Financials

    Live finance-specific insights

    View All

    Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

    First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 Robust preclinical monotherapy anti-tumor activity for both selective CBP and selective EP300 degrader programs Progress with FHD-909, selective CBP, and selective EP300 degrader programs further validates Foghorn's drug discovery engine Conference call and webcast today at 5 pm ET / 2 pm PT CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseas

    4/9/24 4:30:00 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

    Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs Conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, inclu

    3/26/24 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Foghorn Therapeutics Inc.

    SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    10/8/24 5:44:34 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Foghorn Therapeutics Inc.

    SC 13G - Foghorn Therapeutics Inc. (0001822462) (Subject)

    9/20/24 6:00:44 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Foghorn Therapeutics Inc. (Amendment)

    SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    6/10/24 9:48:22 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care